CG
PGNX

Clinton Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Clinton Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-14,996
Closed -$121K – 428
2018
Q2 		$121K Buy
+14,996
New +$114K 0.02% 336

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Clinton Group's PGNX Position: Q3 2018 in Review

Clinton Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 14,996 shares — an estimated $121K sold.

Clinton Group first reported a position in PGNX in Q2 2018 and held it in 1 quarter. The position peaked at $121K in Q2 2018. 149 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

  • Clinton Group reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Clinton Group sold 14,996 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $121K.
  • Clinton Group first reported a position in Progenics Pharmaceuticals Inc in Q2 2018 and held it in 1 quarter.
  • Clinton Group's Progenics Pharmaceuticals Inc position peaked at $121K in Q2 2018.
  • 149 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Clinton Group's 13F filing for Q3 2018, filed 10 Oct 2018.